Primus Aerospace Adopts VELO3D’s Titanium AM System to Unlock the Future of Design for the Aerospace and Defense Industry
16.3.2021 16:15:00 EET | Business Wire | Press release
Primus Aerospace—a leading contract manufacturing partner to aerospace, defense & space OEMs—has joined the VELO3D partner network with the purchase of a Ti6Al4V Sapphire® metal additive manufacturing (AM) system.
This is the first titanium-dedicated metal 3D printer from VELO3D that will be used solely for aerospace & defense applications. Primus has identified VELO3D’s AM system as a solution for many applications they currently produce, including cube satellites, hypersonics and turbine engines. The Colorado-based company is a top-tier supplier for the leading defense primes and the majority of aerospace OEMs, including Lockheed, Boeing, Northrop Grumman, General Dynamics, and Raytheon.
“Primus is proud to be a leader in this manufacturing category,” says Gary Vaillancourt, Vice President of Engineering & Technical Sales. “Our customers require maximum performance of their aerospace-related systems and, together with VELO3D, we can redefine what is possible in manufacturing through advanced AM technology.”
The partnership with VELO3D will enable Primus Aerospace to deliver unique design freedom and highest-quality AM services to their customers. Using the VELO3D manufacturing solution, Primus is looking to unlock powerful design and manufacturing capabilities that will enable the realization of previously unattainable geometries and optimized solutions as well as the exploration of novel aerospace applications.
“Primus Aerospace is an excellent partner for us with their customer focus, commitment to innovation, and adoption of leading-edge technology,” says Benny Buller, founder and CEO of VELO3D. “Our capabilities will help them deliver to engineers and supply chain managers the part designs they want, not the limited part geometries that other commodity-AM suppliers say they can have. The synergies between our two companies will support developers of new products to optimize their designs without compromise or restraint.”
Primus Aerospace expects to take delivery of the titanium Sapphire® System in Q1 2021 and will begin offering titanium printing at their facility located in Golden, Colorado.
Learn more about the VELO3D Contract Manufacturing Partner Network. https://www.velo3d.com/partners/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210316005206/en/
Contact information
Media Contact for Primus:
Gary Vaillancourt
Vice President Engineering & Technical Sales
gvaillancourt@primusaero.com
Media Contact for VELO3D:
Renette Youssef
Chief Marketing Officer
press@velo3d.com
Twitter: https://twitter.com/VELO3DMetal
Facebook: https://www.facebook.com/Velo3Dinc/
LinkedIn: https://www.linkedin.com/company/velo3d/
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays1.9.2026 08:00:00 EEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. "The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “As a pioneer in neurological diagnostics, Fujirebio remains committed to advancing patient care through innovative, fully automated testing solutions." These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions designed to inform clinical decision-making across the
Helical Fusion Named a Final Candidate for Japan’s METI Fusion Power Demonstration Program1.9.2026 05:00:00 EEST | Press release
Helical Fusion Co., Ltd., a fusion energy company developing a Helical Stellarator toward commercially viable fusion power, has been named a final candidate for Japan’s Ministry of Economy, Trade and Industry (METI) program supporting the demonstration of fusion power generation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831991676/en/ Image of Helix HARUKA, Helical Fusion’s Integrated Demo Device(left), and Helix KANATA, Helical Fusion’s Fusion Pilot Plant(right) The program is designed to accelerate fusion power demonstration in the 2030s under Japan’s national energy and fusion strategies. It supports private-sector technology development across multiple fusion approaches, including tokamak, stellarator and laser fusion, with approximately JPY 60 billion in total government support anticipated over the three years through 2028. The amount to be awarded to Helical Fusion will be announced following the formal grant
Strategic Combination of ITC Infotech and Happiest Minds Technologies to Create a Scaled, Future-Ready, AI-First Global Technology Services Enterprise with US$ 1 Billion Revenue by FY28 [1]1.9.2026 00:35:00 EEST | Press release
ITC Infotech (ITCI), a wholly owned subsidiary of ITC Limited and a leading global technology services player, today announced the proposed strategic combination with Happiest Minds Technologies Limited (Happiest Minds) to create a scaled, future-ready, AI-first global technology services enterprise. The ITCI Board approved a proposal to acquire 22.1% equity stake from the promoter of Happiest Minds in two tranches under a Share Purchase Agreement. The transaction would be funded through a Rights Issue by ITC Infotech. ITCI Board has also approved a proposed Scheme of Amalgamation of Happiest Minds with ITCI which will be effected after the share acquisition. Pursuant to the scheme, the shares of ITCI will be listed on the stock exchanges. The proposed transaction has also been endorsed by the Board of Directors of ITC Limited. This strategic combination will synergistically blend ITCI’s AI-led capabilities across Cloud, Data Analytics, PLM, SAP, enterprise transformation, industry-spe
Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule31.8.2026 22:07:00 EEST | Press release
Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations. Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.” “Our main focus is to provide great service to and being a rock-solid partner for our cu
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 22:00:00 EEST | Press release
BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional research, development, and manufacturing to deliver breakthrough cancer treatments worldwide.” Improved access to oncol
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom